tolebrutinib
sanofi
['tolebrutinib']
treatment with #tolebrutinib 60 mg per day was safe and associated with low annualized relapse rate and stable #disability through 120 weeks for those with relapsing-remitting #ms, according to research presented at #aanam. 
The content you need, when you need it.